CA2530668A1 - Produit comprenant au moins un inhibiteur de phosphatase cdc25 en association avec au moins un autre agent anti-cancereux - Google Patents

Produit comprenant au moins un inhibiteur de phosphatase cdc25 en association avec au moins un autre agent anti-cancereux Download PDF

Info

Publication number
CA2530668A1
CA2530668A1 CA002530668A CA2530668A CA2530668A1 CA 2530668 A1 CA2530668 A1 CA 2530668A1 CA 002530668 A CA002530668 A CA 002530668A CA 2530668 A CA2530668 A CA 2530668A CA 2530668 A1 CA2530668 A1 CA 2530668A1
Authority
CA
Canada
Prior art keywords
radical
alkyl
independently
radicals
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002530668A
Other languages
English (en)
French (fr)
Inventor
Gregoire Prevost
Marie-Christine Brezak Pannetier
Christian Diolez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2530668A1 publication Critical patent/CA2530668A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002530668A 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphatase cdc25 en association avec au moins un autre agent anti-cancereux Abandoned CA2530668A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR03/07649 2003-06-25
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
PCT/FR2004/001586 WO2005000852A2 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux

Publications (1)

Publication Number Publication Date
CA2530668A1 true CA2530668A1 (fr) 2005-01-06

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002530668A Abandoned CA2530668A1 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphatase cdc25 en association avec au moins un autre agent anti-cancereux

Country Status (14)

Country Link
US (3) US20060281736A1 (cg-RX-API-DMAC7.html)
EP (3) EP1641453B1 (cg-RX-API-DMAC7.html)
JP (2) JP2007514639A (cg-RX-API-DMAC7.html)
AR (2) AR044930A1 (cg-RX-API-DMAC7.html)
AT (1) ATE439836T1 (cg-RX-API-DMAC7.html)
CA (1) CA2530668A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004022674D1 (cg-RX-API-DMAC7.html)
DK (1) DK1641453T3 (cg-RX-API-DMAC7.html)
ES (1) ES2332137T3 (cg-RX-API-DMAC7.html)
FR (1) FR2856688B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000216A (cg-RX-API-DMAC7.html)
MY (1) MY141725A (cg-RX-API-DMAC7.html)
PL (1) PL1641453T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005000852A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) * 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2366874T3 (es) * 2007-09-06 2011-10-26 Basf Se Mezclas de poliariléteres ramificados y polímeros hidrófilos.
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
UY32776A (es) 2009-07-09 2011-02-28 Irm Llc Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
US20210106567A1 (en) * 2019-10-01 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
JP2004516297A (ja) * 2000-12-20 2004-06-03 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) サイクリン依存性キナーゼ(cdk)及びグリコーゲンシンターゼキナーゼ−3(gsk−3)の阻害剤
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
AR044930A1 (es) 2005-10-12
DE602004022674D1 (de) 2009-10-01
MY141725A (en) 2010-06-15
WO2005000852A3 (fr) 2005-06-30
EP1641453B1 (fr) 2009-08-19
EP1792905A1 (fr) 2007-06-06
FR2856688A1 (fr) 2004-12-31
WO2005000852A2 (fr) 2005-01-06
AR070977A2 (es) 2010-05-19
JP2009149694A (ja) 2009-07-09
FR2856688B1 (fr) 2008-05-30
MXPA06000216A (es) 2006-04-11
EP2335702A1 (fr) 2011-06-22
US20060281736A1 (en) 2006-12-14
ES2332137T3 (es) 2010-01-27
US20090253685A1 (en) 2009-10-08
DK1641453T3 (da) 2009-12-14
PL1641453T3 (pl) 2010-01-29
US20090137596A1 (en) 2009-05-28
EP1641453A2 (fr) 2006-04-05
JP2007514639A (ja) 2007-06-07
ATE439836T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
US20090137596A1 (en) G-protein inhibitor
US20090131428A1 (en) Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
CA2448528A1 (fr) Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
WO2008049994A1 (fr) Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90
EP1831209B1 (fr) Inhibiteurs de phosphatases cdc25
CA2727626A1 (fr) Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
US7495021B2 (en) Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
EP1641789A2 (fr) Benzothiazole-4,7-diones et benzoxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
EP1814879B1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20121105